Nasdaq
$4.84▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $45.5MShares out 9.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
6- 9.22After-hours26.09.23 05:208-KKey event#●●●#●●●
LeonaBio, Inc.
LeonaBio announced that Series A common warrants to purchase 23,031,494 shares, issued in December 2025, became exercisable on September 18, 2026. The warrants have an exercise price of $6.35 per share and, if fully exercised for cash, would provide the company with approximately $146.2 million in additional capital. The exercise period for these warrants runs through October 19, 2026.…more
$4.84+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.3Regular26.09.04 04:383Ownership
LeonaBio, Inc.
Insider David J. Portman of LeonaBio, Inc. has filed an initial statement of beneficial ownership (Form 3) as of August 24, 2026. This filing serves as the initial report regarding his equity holdings in the company.…more
$4.84+0.00%vs prev closeView filingShare - 8.31After-hours26.09.01 05:31SCHEDULE 13DOwnership
LeonaBio, Inc.
Sermonix Pharmaceuticals, Inc. has filed a SCHEDULE 13D, reporting that it has acquired more than 5% ownership of LeonaBio, Inc. This filing indicates that a significant shareholder has obtained a substantial stake capable of influencing the company's management or corporate governance.…more
$4.84+0.00%vs prev closeView filingShare
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.3Pre-market26.09.03 20:00#●●●#●●●
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
LeonaBio announced that its management will participate in the Cantor Global Healthcare Conference 2026 scheduled for September 11. The company will conduct a fireside chat to discuss its business and clinical developments.…more
$4.84+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 8.26After-hours26.08.27 05:43
●●●●●●●● ●●●●● ●●●●●●
LeonaBio has successfully enrolled the 500th subject in its Phase 3 ELAINE-3 clinical trial for lasofoxifene in combination with abemaciclib. While the trial is progressing, the impact on the stock remains neutral as final efficacy data is not yet available.…more
$4.84+0.00%vs prev closeShareBenzinga - 8.14After-hours26.08.15 05:05
●●●●●●●● ●●●●● ●●●●●●
LeonaBio announced it is on track to complete patient enrollment for its Phase 3 ELAINE-3 trial of lasofoxifene in the fourth quarter of 2026. The company expects to report topline data in the second half of 2027, marking a key milestone in its clinical development.…more
$4.84+0.00%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report